# Junji Furuse

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/junji-furuse/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,783 |
| Field | Pancreatic and Hepatic Oncology Research |
| h-index | 75 |
| i10-index | 300 |
| Last Known Institution | Kanagawa Prefectural Hospital Organization |
| OpenAlex ID | https://openalex.org/A5056197140 |
| ORCID iD | https://orcid.org/0000-0003-0663-6117 |
| Works | 724 |

## Researcher papers

- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study](https://scholariq.org/papers/randomized-phase-iii-study-of-gemcitabine-plus-s-1-s-1-alone-or-gemcitabine/)
- [Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies](https://scholariq.org/papers/clinical-utility-of-circulating-tumor-dna-sequencing-in-advanced/)
- [Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial](https://scholariq.org/papers/combination-gemcitabine-plus-s-1-versus-gemcitabine-plus-cisplatin-for-advanced/)
- [Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study](https://scholariq.org/papers/nivolumab-alone-or-in-combination-with-cisplatin-plus-gemcitabine-in-japanese/)
- [Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-s-1-compared-with-observation-in-resected-biliary-tract-cancer-jcog1202/)

## Researcher topics

- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Kanagawa Prefectural Hospital Organization](https://scholariq.org/institutions/kanagawa-prefectural-hospital-organization/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.